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Abstract	
Derailment	of	the	PI3K-AGC	protein	kinase	signalling	network	contributes	to	many	human	
diseases	including	cancer.	Recent	work	has	revealed	that	the	poorly	studied	AGC	kinase	
family	member,	SGK3	promotes	resistance	to	cancer	therapies	that	target	the	Class	1	PI3K	
pathway,	by	substituting	for	loss	of	Akt	kinase	activity.	SGK3	is	recruited	and	activated	at	
endosomes,	by	virtue	of	its	PX	domain	binding	to	PtdIns(3)P.	Here	we	demonstrate	that	
endogenous	SGK3	is	rapidly	activated	by	growth	factors	such	as	IGF1,	through	pathways	
involving	both	Class	1	and	Class	3	PI3Ks.	We	provide	evidence	that	IGF1	enhances	
endosomal	PtdIns(3)P	levels	via	a	pathway	involving	the	UV-RAG	complex	of	hVPS34	Class	3	
PI3K.	Our	data	points	towards	IGF1	induced	activation	of	Class	1	PI3K	stimulating	SGK3	
through	enhanced	production	of	PtdIns(3)P	resulting	from	the	dephosphorylation	of	
PtdIns(3,4,5)P3.	Our	findings	are	also	consistent	with	activation	of	Class	1	PI3K	promoting	
mTORC2	phosphorylation	of	SGK3	and	with	oncogenic	Ras	activating	SGK3	solely	through	
the	Class	1	PI3K	pathway.	Our	results	highlight	the	versatility	of	upstream	pathways	that	
activate	SGK3	and	help	explain	how	SGK3	substitutes	for	Akt	following	inhibition	of	Class	1	
PI3K/Akt	pathways.	They	also	illustrate	robustness	of	SGK3	activity	that	can	remain	active	
and	counteract	physiological	conditions	or	stresses	where	either	Class	1	or	Class	3	PI3K	
pathways	are	inhibited.	
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Introduction	
SGK3	(Serum	and	Glucocorticoid	Regulated	Kinase	Family	Member	3)	belongs	to	the	AGC	
family	of	protein	kinases	that	orchestrate	a	wide	range	of	biological	responses	including	
controlling	cell	growth,	proliferation,	metabolism	and	intracellular	trafficking	possesses	[1].	
Disruptions	in	diverse	AGC	kinase	signalling	pathways	as	well	as	the	upstream	PI3-kinase	
(phosphoinositide	3-kinase)	pathways	that	control	their	activity,	contribute	to	major	
diseases	such	as	cancer,	inflammation	heart	failure	and	diabetes	[2].	Like	other	members	of	
the	AGC	kinases	including	closely	related	Akt	isoforms,	SGK3	is	activated	following	
phosphorylation	of	its	kinase	domain	T-loop	Thr320	residue	by	PDK1	(3-phosphoinositide	
dependent	kinase-1)	and	phosphorylation	of	its	C-terminal	Ser422	hydrophobic	motif	
residue	by	mTORC2	(mTOR	Complex	2) [3, 4].	Like	other	AGC	kinase	members,	
phosphorylation	of	the	hydrophobic	residue	of	SGK3	by	mTORC2	promotes	T-loop	
phosphorylation	and	activation	by	PDK1	[5-7]).	The	two	other	SGK	isoforms	namely,	SGK1	
and	SGK2,	do	not	possess	any	phosphoinositide	binding	domain	and	their	activity	is	
regulated	by	mTORC2	phosphorylating	the	hydrophobic	motif	residue,	triggering	activation	
by	PDK1	[5,	8,	9].	
	
SGK3	possesses	an	N-terminal	PtdIns(3)P-binding	PX	domain,	that	enables	it	to	associate	
with	endosomal	membranes,	where	a	large	fraction	of	the	cellular	pool	of	PtdIns(3)P	is	
located	[6,	10,	11].	Endosomal	PtdIns(3)P	is	generated	by	the	Class	3	PI3K	family	member	
termed	hVps34	(human	vacuolar	protein	sorting	34),	that	phosphorylates	PtdIns	to	generate	
PtdIns(3)P	[12]	.	PtdIns(3)P	can	also	be	generated	through	breakdown	of	PtdIns(3,4,5)P3	
resulting	from	the	activation	of	Class	1	PI3Ks [13],	where	PtdIns(3,4,5)P3	is	converted	to	
PtdIns(3)P	via	the	sequential	actions	of	the	phosphatidylinositol	5-phosphatase	(SHIP2)	[14]	
and	phosphatidylinositol	4-phosphatases	(INPP4A/B)	[15].	PtdIns(3)P	is	rapidly	
dephosphorylated	in	cells	to	PtdIns	by	a	family	of	myotubularin	PtdIns	3-phosphatases	[16].	
Mutations	that	ablate	PX	domain	PtdIns(3)P	binding	or	treatment	of	cells	with	hVps34	
inhibitors,	blocked	SGK3	endosomal	localisation	as	well	as	suppressing	kinase	activity,	by	
lowering	phosphorylation	of	T-loop	and	hydrophobic	motifs	[6].	Recent	biochemical	studies	
suggested	that	PtdIns(3)P	binding	to	the	PX	domain,	promotes	SGK3	phosphorylation	of	the	
T-loop	residue	by	PDK1	[17].		
		
Instead	of	an	N-terminal	PX	domain,	Akt	kinases	possess	a	Pleckstrin	Homology	(PH)	domain	
that	binds	to	the	plasma	membrane	localised	PtdIns(3,4,5)P3	generated	in	response	to	
agonists	that	trigger	activation	of	Class	1	PI3Ks	[18,	19].	Akt	will	also	bind	to	the	immediate	
breakdown	product	of	PtdIns(3,4,5)P3,	namely	PtdIns(3,4)P2	a	reaction	catalysed	by	SHIP2	
(SH2-Containing	Inositol	5ʹ-Phosphatase)	[14,	20].	Analogous	to	SGK3,	binding	of	Akt	to	
PtdIns(3,4,5)P3/PtdIns(3,4)P2	induces	a	conformational	change	that	promotes	
phosphorylation	of	the	Thr308	T-loop	residue	by	PDK1	[21-23].	mTORC2	mediated	
phosphorylation	of	the	Ser473	hydrophobic	motif	residue	of	Akt,	also	promotes	PDK1	
phosphorylation	of	the	T-loop	residue	[24].	Once	activated,	Akt	controls	critical	processes	
such	as	metabolism	and	growth	by	phosphorylating	dozens	of	key	targets	including	FOXO	
(forkhead	box	O)	transcription	factors,	TSC2	(tuberous	sclerosis	complex	2),	NDRG1	(N-Myc	
Downstream	Regulated)	and	GSK3	(glycogen	synthase	kinase	3)	[19].		
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Akt	and	SGK	possess	similar	substrate	specificities	and	can	phosphorylate	overlapping	
substrates	[25-27].	A	significant	proportion	of	breast	cancer	cells	with	mutations	in	PTEN	or	
Class	1	PI3K	are	inherently	resistant	to	inhibitors	of	PI3K	or	Akt,	as	they	express	high	levels	
of	SGK1	that	can	substitute	for	Akt	[27,	28].	In	human	clinical	trials,	long-term	
administration	of	a	Class	1	PI3Ka	inhibitor	(BYL719)	resulted	in	metastatic	tumours	in	some	
patients	that	became	resistant	to	the	inhibitor	by	upregulating	SGK1	[28].	In	another	study,	
prolonged	treatment	of	breast	cancer	cell	lines	with	Class	1	PI3K	or	Akt	inhibitors	induced	
resistance,	by	increasing	expression	and	activation	of	SGK3	[17].	Treatment	of	BT-474	breast	
cancer	cell-derived	tumours	in	a	xenograft	model	with	a	combination	of	SGK	and	Akt	
inhibitors	induced	greater	tumour	regression	than	achieved	through	administration	of	
either	inhibitor	alone	[17].		
	
In	this	study,	we	investigate	how	the	activity	of	endogenous	SGK3	is	controlled.	We	find	that	
SGK3	is	rapidly	stimulated	by	growth	factors	through	a	pathway	that	involves	both	Class	1	
and	Class	3	PI3Ks.	Our	data	are	consistent	with	a	model,	in	which	growth	factors	stimulate	
SGK3	activity	by	enhancing	endosomal	PtdIns(3)P	production	via	the	UV-RAG	complex	of	
hVPS34	as	well	as	through	a	pathway	involving	SHIP2-controlled	metabolism	of	
PtdIns(3,4,5)P3	produced	by	Class	1	PI3K,	to	PtdIns(3)P.	These	findings	highlight	the	
adaptability	of	the	mechanisms	controlling	activation	of	SGK3.		
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Materials	and	Methods	
	
Materials.	[γ-32P]ATP	was	from	PerkinElmer.	Triton	X-100,	EDTA,	EGTA,	sodium	
orthovanadate,	sodium	glycerophosphate,	sodium	fluoride,	sodium	pyrophosphate,	2-
mercaptoethanol,	sucrose,	benzamidine,	Tween	20,	Tris/HCl,	sodium	chloride,	magnesium	
acetate	and	doxycyclin	were	from	Sigma.	PMSF	was	from	Melford.	Protein	G–Sepharose	was	
from	GE	Healthcare.	Tissue	culture	reagents,	Novex	4–12%	Bis-Tris	gels	and	NuPAGE	LDS	
sample	buffer	was	from	Invitrogen	(NP0008).	Polyethylenimine	was	from	Polysciences.	
Polybrene	was	from	Sigma.	Ampicillin	was	from	Merck.	P81	phosphocellulose	paper	was	
from	Whatman.	Methanol	and	chloroform	were	from	VWR	Chemicals.	1,2-dioleoyl-sn-
glycero-3-phosphoinositol	was	from	Avanti	Polar	Lipids.	Inhibitors	GDC-0941	(Axon	
Medchem)	and	MK-2206	(Selleck)	were	purchased	from	the	indicated	suppliers.	VPS34-IN1	
(1-[[2-[(2-chloropyridin-4yl)amino]-4ʹ-(cyclopropylmethyl)-[4,5ʹ-bipyrimidin]-2ʹ-yl]amino]-2-
methyl-propan-2-ol)	was	synthesized	as	described	in	patent	WO	2012085815	A1	as	
described	before	[6].	The	Sanofi	compound	14h	was	synthesised	as	described	previously	
[29].	Plasmids	used	in	the	present	study	were	generated	by	the	MRC-PPU	reagents	and	
Services	team	(https://mrcppureagents.dundee.ac.uk/)	including	HA-SHIP2	(DU27327),	HA-
NRAS	G12D	(DU52590),	HA-KRAS	G12C	(DU26569),	HA-KRAS	G12D	(DU26536),	HA-ERBB2	
V842I	(DU26611)	and	HA-EGFR	L833R	(DU26542).	All	DNA	constructs	were	verified	by	DNA	
sequencing,	performed	by	the	MRC-PPU	DNA	Sequencing	and	Service	
(http://www.dnaseq.co.uk).	All	constructs	are	available	to	request	from	the	MRC-PPU	
reagents	webpage	(http://mrcppureagents.dundee.ac.uk)	and	the	unique	identifier	(DU)	
numbers	indicated	above	provide	direct	links	to	the	cloning	and	sequence	details.	The	
retroviral	expression	system	vectors	pCMV-Gag-Pol	and	pCMV-VSVG	constructs	were	from	
Clontech.	
	
Cell	culture,	transfection	and	cell	lysis.	HEK293	cells	were	purchased	from	the	American	
Tissue	Culture	Collection	and	cultured	in	DMEM	media	supplemented	with	10%	(v/v)	foetal	
bovine	serum,	2	mM	L-glutamine,	100	U/ml	penicillin	and	0.1	mg/ml	streptomycin.	Inhibitor	
treatments	were	carried	out	as	described	in	figure	legends.	The	cells	were	lysed	in	buffer	
containing	50	mM	Tris/HCl	(pH	7.5),	1	mM	EGTA,	1	mM	EDTA,	1%	(v/v)	Triton	X-100,	1	mM	
sodium	orthovanadate,	50	mM	NaF,	5	mM	sodium	pyrophosphate,	0.27	M	sucrose,	10	mM	
sodium	2-glycerophosphate,	0.2	mM	phenylmethylsulfonyl	fluoride	and	1	mM	benzamidine.	
Lysates	were	clarified	by	centrifugation	at	16,000	g	for	10	min	at	4°C.	Protein	concentration	
was	calculated	using	Bradford	assay	(Thermo	Scientific).	Immunoblotting	and	
immunoprecipitation	were	performed	using	standard	procedures.	The	signal	was	developed	
using	ECL	Western	Blotting	Detection	Kit	(Amersham)	on	Amersham	Hyperfilm	ECL	film	
(Amersham).		
	
Antibodies.	The	following	antibodies	were	raised	in	sheep,	by	the	MRC-PPU	reagents	and	
Services	team	(https://mrcppureagents.dundee.ac.uk/)	and	affinity	purified	against	the	
indicated	antigens:	anti-Vps34	(S672B;	3rd	bleed;	raised	against	full	length	human	
Vps34)(DU3303),	anti-Beclin1	(S900B;	1st	bleed;	raised	against	full-length	human	
Beclin1)(DU7159),	Anti-UV-RAG	(S323D;	3rd	bleed;	raised	against	full-length	human	UV-
RAG)(DU	36785),	anti-Akt1	(S695B,	third	bleed;	raised	against	residues	466–480	of	human	
Akt1:	RPHFPQFSYSASGTA),	anti-NDRG1	(S276B	third	bleed;	raised	against	full-length	human	
NDRG1)	(DU1557),	anti-SGK3	(S037D	third	bleed;	raised	against	human	SGK3	PX	domain	
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comprising	residues	1–130	of	SGK3),	anti-PRAS40	(proline-rich	Akt	substrate	40	kDa)	(S115B,	
first	bleed;	raised	against	residues	238–256	of	human	PRAS40:	DLPRPRLNTSDFQKLKRKY)	and	
anti-(phospho-PRAS40	Thr246)	(S114B,	second	bleed;	raised	against	residues	240–251	of	
human	PRAS40:	CRPRLNTpSDFQK).	Anti-Vps15	was	raised	in	rabbit	(R1737;	3rd	bleed;	raised	
against	residues	433-667)	(DU	39129).	Anti-phospho-Akt	Thr308	(#4056),	anti-phospho-
NDRG1	Thr346	(#5482),	anti-EEA1	(#2411),	anti-SIN1	(#12860),	anti-GAPDH	(#2118)	and	
anti-phospho-SGK3	Thr320	(#5642)	antibodies	were	purchased	from	Cell	Signalling	
Technology.	GFP-Trap®	beads	(gta-10)	and	rat	anti-GFP	antibody	(3H9)	were	purchased	
from	Chromotek.	Secondary	antibodies	coupled	to	HRP	(horseradish	peroxidase)	were	
obtained	from	Thermo	Scientific.	
	
Immunoprecipitation	and	assay	of	SGK3	and	Akt.	In	vitro	kinase	activity	of	SGK3	and	Akt	
was	assayed	by	measuring	[γ-32P]ATP	incorporation	into	Crosstide	substrate	peptide	
[GRPRTSSFAEGKK]	[6,	30].	Endogenous	SGK3	or	Akt	was	immunoprecipitated	from	2	mg	
HEK293	cell	lines	using	an	anti-SGK3	antibody	(S037D,	3rd	bleed)	or	an	anti-Akt	antibody	
(S695B,	3rd	bleed).	Immunoprecipitates	were	washed	in	sequence	with	lysis	buffer	
containing	high	salt	concentration	(500	mM	NaCl),	low	salt	concentration	(150	mM)	and	
buffer	A	(50	mM	Tris/HCl,	pH	7.5,	and	0.1	mM	EGTA).	Reactions	were	carried	in	40	μl	of	
total	volume	containing	0.1	mM	[γ-32P]ATP	(400–1000	c.p.m./pmol),	10	mM	magnesium	
acetate	and	30	μM	Crosstide	peptide.	Reactions	were	terminated	by	adding	10	μl	of	0.1	mM	
EDTA	and	spotting	40	μl	of	the	reaction	mixture	on	P81	paper	which	were	immediately	
immersed	into	50	mM	orthophosphoric	acid.	Papers	were	washed	several	times	in	50	mM	
orthophosphoric	acid,	rinsed	in	acetone	and	air	dried.	Radioactivity	was	quantified	by	
Cerenkov	counting.	One	unit	of	enzyme	activity	was	defined	as	the	amount	of	enzyme	that	
catalyses	incorporation	of	1	nmol	of	[γ-32P]ATP	into	the	substrate	over	1	min.	
	
In	vitro	kinase	assays	of	hVPS34	and	UV-RAG.	Cells	were	treated	as	described	in	figure	
legends	prior	to	lysis	in	NP-40	lysis	buffer	(50	mM	Hepes	pH	7.4,	150	mM	NaCl,	1	mM	EDTA,	
10%	(v/v)	glycerol,	0.5%	NP-40).	Endogenous	GFP-UV-RAG	or	GFP-Vps34	was	
immunoprecipitated	using	10	µl	GFP-Trap®	beads	(Chromotek)	and	2	mg	of	clarified	cell	
extract.	The	immunoprecipitates	were	subjected	to	PI3K	assays	essentially	as	described	
before	[31,	32].	Beads	were	washed	twice	in	NP-40	lysis	buffer	containing	high	salt	
concentration	(500	mM	NaCl),	twice	with	NP-40	lysis	buffer	and	finally	twice	with	lipid	
kinase	assay	(LKA)	buffer	(10	mM	MnCl2,	20	mM	Tris	pH	7.5,	67	mM	NaCl,	0.02%	(w/v)	
CHAPS).	hVPS34	PI	3-kinase	activity	was	assayed	in	a	final	volume	of	40	µl	containing	10	μg	
phosphatidylinositol	liposomes	(bovine	liver	Phosphoinositide,	extruded	through	a	100-nm	
filter—Avanti	Mini-Extruder),	5	μM	ATP	and	7.5	μCi	32P	γ-ATP	in	LKA	buffer.	Reactions	were	
agitated	for	30	min	at	30°C	before	centrifugation	through	a	Spin-X	column	to	separate	the	
32P-labelled	phosphatidylinositol	in	the	flow	through	and	the	immunoprecipitated	hVPS34	
complex	bound	to	the	beads.	A	mixture	of	500	μl	of	methanol:chloroform:hydrocholoric	
acid	(200:100:3.5)	was	added	to	the	flow	through	and	90	µl	of	2×	LDS	sample	buffer	added	
to	the	beads	and	the	resulting	suspension	heated	at	70	oC	for	10	min	to	elute	protein.	In	
order	to	extract	the	32P-labelled	phosphatidylinositol	3-phosphate	from	the	flow	through,	
180	μl	of	chloroform	and	300	μl	of	0.1	M	hydrochloric	acid	were	added	and	the	samples	
vortexed	gently	and	then	centrifuged	at	1,000	g	for	1	min	at	room	temperature.	The	lower	
lipid-containing	chloroform	layer	was	retained	and	dried	by	centrifugal	evaporation.	Lipids	
were	re-dissolved	in	60	µl	chloroform	and	spotted	onto	thin	layer	chromatography	plates	
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(Silica	60,	Merck-Millipore)	activated	in	potassium	oxalate	(1%	(w/v)	potassium	oxalate,	
5	mM	EDTA,	50%	(v/v)	methanol).	Chromatography	was	undertaken	in	a	solvent	system	
comprising	methanol:chloroform:water:ammonium	hydroxide	(47:60:11.2:2)	to	separate	
phosphatidylinositol	substrate	and	32-P	labelled	phosphatidylinositol	3-phosphate	product.	
Once	dried,	the	plate	was	subjected	to	autoradiography	in	order	to	visualize	32-P	labelled	
phosphatidylinositol	3-phosphate.	
	
PtdIns(3)P	PX	Domain	Staining	and	Immunofluorescence.	For	selective	PtdIns(3)P	staining,	
the	GST	tagged	HRS	2	x	FYVE	domain	(residues	147-223)	and	the	mutant	GST	tagged	2x	FYVE	
(residues	147-223)	H176A	H177A	(DU47684)	were	expressed	in	E.coli	(BL21)	and	purified	
over	a	glutathione	column	using	standard	procedures.	The	recombinant	wild	type	protein	
was	chemically	conjugated	to	Alexa	Fluor-488	and	the	mutant	conjugated	to	Alexa-Fluor	594	
using	the	Alexa	Fluor	Microscale	Protein	Labelling	Kit	(#	A30008)	as	per	manufacturers	
protocol.	For	staining,	a	similar	protocol	that	described	before	was	followed	[32].	Following	
treatment	described	in	the	figure	legends,	cells	were	washed	once	on	ice	with	phosphate	
buffered	saline	(PBS)	and	glutamate	buffer	(25	mM	Hepes	pH	7.4,	25	mM	KCl,	2.5	mM	
MgAcetate,	5	mM	EGTA,	150	mM	Potassium	Glutamate).	Coverslips	were	then	immediately	
snap	frozen	in	liquid	nitrogen	and	thawed	at	room	temperature	for	0.5	min	prior	to	two	
further	washes	with	ice	cold	glutamate	buffer	prior	to	fixing	by	incubating	cells	in	3.7%	(w/v)	
formaldehyde,	200	mM	Hepes	pH7.4.	After	30	min	at	room	temperature,	fixed	cells	were	
quenched	by	incubating	twice	for	10	min	in	10	mM	Hepes,	pH	7.4,	DMEM	at	room	
temperature.	Samples	were	blocked	by	washing	twice	with	blocking	buffer	(phosphate	
buffered	saline	containing	1%	(w/v)	bovine	serum	albumin)	and	then	incubated	in	this	
buffer	for	a	further	30	min.	Coverslips	were	next	incubated	for	1h	at	room	temperature	with	
5	µg/ml	wild	type	and	mutant	dye-labelled	FYVE	domain	mixed	together.	Cells	were	then	
washed	three	times	in	blocking	buffer.	Coverslips	were	washed	once	more	in	water	and	
mounted	using	ProLong	Gold	Antifade	(ThermoFisher	#P36931).	For	visualisation	of	SGK3-
GFP,	GFP-Vps34	and	UV-RAG-GFP,	the	GFP	signal	was	enhanced	using	a	chicken	anti-GFP	
antibody	(Abcam)	followed	by	anti-chicken	secondary	antibody	conjugated	to	Alexa	Fluor	
488.	EEA1	was	co-stained	with	anti-EEA1	antibody	and	secondary	anti-rabbit	antibody	
conjugated	to	Alexa	Fluor	594.	Prior	to	staining,	cells	were	fixed	with	4%	(v/v)	
paraformaldehyde	and	permeabilised	with	1%	(v/v)	NP-40.	The	images	were	collected	on	an	
LSM710	laser	scanning	confocal	microscope	(Carl	Zeiss)	using	the	x63	Plan	-	Apochromat	
objective	(NA	1.4),	using	a	pinhole	chosen	to	provide	a	uniform	0.8um	optical	section	
thickness	in	all	the	fluorescence	channels.	Images	from	the	microscope	were	imported	into	
Volocity	image	processing	software	(Perkin-Elmer)	and	batch	processed	using	the	same	
custom	written	programmes	for	all	the	images	in	an	experimental	group.	For	example,	in	
each	image	endosomes	were	identified	from	the	EEA1	antibody	staining	and	the	intensity	of	
the	GFP	tagged	protein	in	these	objects	was	collected	as	the	sum	of	the	pixel	intensities,	
normalised	for	the	number	of	cells	in	each	image	(counted	from	the	number	of	DAPI	nuclei).	
The	graphs	show	the	sum	of	the	GFP	intensity	per	cell	in	arbitrary	units	with	variation	
presented	as	SEM	for	the	15	images	collected	from	each	slide.	Each	treatment	was	repeated	
3	times	and	graphs	shown	are	from	representative	experiments.	
	
	
	
	 8	
Generation	of	SGK3,	SHIP2	and	Sin1	knock	out	cell	lines	and	GFP-Vps34,	UV-RAG-GFP	&	
SGK3-GFP	knock	in	cell	lines	using	Crispr/Cas9	genome	editing.	
A	modified	Cas9	nickase	system	[33]	was	used	for	the	generation	of	N-terminal	GFP-VPS34,	
C-terminal	GFP-UV-RAG	and	C-terminal	SGK3	knock-in	mutation.	Optimal	sgRNA	pairs	were	
identified	(as	close	as	possible	to	point	of	GFP	insertion,	with	a	low	combined	off-targeting	
score	((VPS34-sgRNA1:	GCTACATCTATAGTTGTGACC	(DU52071);	sgRNA2:	
GCCCCATCGCACCGTCTGCAA	(DU52082);	UV-RAG-sgRNA1:	GCACTTATCGGAACTCCTGCG	
(DU54207);	sgRNA2:	GCAGGTCAACAGTAGGACTG	(DU54212);	SGK3-sgRNA1:	
GCATCATCTGCCTCCAATACAC(TGG)	(DU48560));	sgRNA2:	GAGGCAGATGATGCATTCGT(TGG)	
(DU	48555).	Complementary	oligos	with	BbsI	compatible	overhangs	were	designed	for	each	
and	the	dsDNA	guide	inserts	ligated	into	BbsI-digested	target	vectors;	the	antisense	guides	
(sgRNA2)	were	cloned	onto	the	spCas9	D10A	expressing	pX335	vector	(Addgene	plasmid	no.	
42335)	and	the	sense	guides	(sgRNA1)	into	the	puromycin-selectable	pBABED	P	U6	plasmid	
(Dundee-modified	version	of	the	original	Cell	Biolabs	pBABE	plasmid).	Donor	constructs	
(VPS34-DU52175,	UV-RAG-DU54245	and	SGK3-DU48103)	consisting	of	GFP	flanked	by	
approximately	500	bp	homology	arms	were	synthesized	by	GeneArt	(Life	Technologies);	
each	donor	was	engineered	to	contain	sufficient	silent	mutations	to	prevent	recognition	and	
cleavage	by	Cas9	nuclease.	sgRNA	pairs	for	the	SGK3	knock	out	were	as	follows:	SGK3-
sgRNA1:	GTTTTGGACTGTCCATTTGA(AGG)	(DU48668);	sgRNA2:	
GTCAGATCCATCTGAAGATG(AGG)	(DU48667)	and	for	SHIP2	KO	as	follows:	sgRNA1:	
GCGTGTGGATGGCTGCGGAGC	(DU52294);	sgRNA2:	GGCCAAGACCATCCCCGTGC	(DU52275).	
sgRNA	pairs	for	the	SIN1	knock	out	were	as	follows;	sgRNA1:	GTGCTGGCAGTATACAAGCGA	
(DU52278);	sgRNA2	GCCCGATCAGGTCCTGCACCC	(DU52297).	HEK293	cells	were	transfected	
with	1	µg	each	of	appropriate	guides	pairs	(pBABED-Puro-sgRNA1	and	pX335-CAS9-D10A-
sgRNA2),	in	addition	to	3	µg	of	the	appropriate	donor	plasmid	for	knock	in	cell	lines.	16	h	
post-transfection,	cell	selection	was	carried	out	using	2	µg/ml	puromycin	for	2	days.	
Transfection	and	selection	was	repeated	prior	to	single	cell	sorting	by	FACS.	Single	cells	
were	plated	in	individual	wells	of	96-well	plates	and	viable	clones	expanded.	Loss	of	protein	
in	knock	out	clones	or	integration	of	GFP	at	the	target	locus	for	knock	in	clones	was	verified	
by	western	blotting	and	genomic	DNA	sequencing	of	the	targeted	locus.	
	
Affinity	directed	protein	missile	(AdPROM)	mediated	knockdown	of	hVPS34	and	UV-RAG.	
The	cDNAs	encoding	the	nanobodies	aGFP16-DU54238	and	VHL-aGFP16	(DU54294)	were	
cloned	into	pBABED-Puro	vectors	(Cell	Biolabs,	modified)	for	constitutive	expression	as	
described	before	[34].	Target	cells	were	retrovirally	transduced.	Briefly,	for	retrovirus	
production,	pBABED	retroviral	plasmids	(6	µg),	encoding	appropriate	proteins	were	co-
transfected	with	pCMV-gag-pol	(4	µg)	and	pCMV-VSV-G	(2	µg)	in	a	10-cm	diameter	dish	of	
70%	confluent	293-FT	cells.	Plasmids	were	mixed	in	0.6	ml	Optimem	(Life	Technologies),	to	
which	24	μl	of	1	mg/ml	polyethylenimine	was	added.	Following	a	15	minute	incubation	at	
room	temperature,	the	mixture	was	applied	drop-wise	to	293-FT	cells.	The	medium	was	
replaced	16	h	post-transfection	with	fresh	medium	and	retrovirus	was	collected	in	the	
growth	medium	24	h	later	following	filtration	through	0.45	µm	filters.	Target	cells	(approx.	
60%	confluent)	were	infected	with	the	optimized	titre	of	retrovirus	medium	supplemented	
with	10	µg/ml	polybrene	for	24	h	prior	to	selection	with	2	µg/ml	puromycin.	
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Mass	spectrometry	measurements	of	inositol	lipids.	Mass	spectrometry	was	used	to	
measure	inositol	lipid	levels	essentially	as	previously	described	[35],	using	a	QTRAP	4000	(AB	
Sciex)	mass	spectrometer	and	employing	the	lipid	extraction	and	derivatization	method	
described	for	cultured	cells,	with	the	modification	that	10ng	C17:0/C16:0	PtdIns(3,4,5)P3	
internal	standard	(ISD)	and	10ng	C17:0/C16:0	PtdIns	ISD	were	added	to	primary	extracts,	
and	that	final	samples	were	dried	in	a	speed	vac	concentrator	rather	than	under	N2.	
Measurements	were	conducted	on	triplicate	samples	per	condition.	PtdIns(3,4,5)P3	
response	ratio	was	calculated	by	dividing	the	PtdIns(3,4,5)P3	response	area	by	the	response	
area	of	PIP3	ISD	in	each	sample.	PtdIns(3,4,5)P3	responses	were	normalised	to	PI	response	
ratio	to	account	for	any	cell	input	variability.	
	
Statistical	analysis	
All	experiments	in	the	present	study	were	performed	at	least	twice	and	similar	results	were	
obtained.	Data	were	analysed	using	one-way	ANOVA	followed	by	Bonferroni's	post-hoc	test	
(P<0.05)	using	Prism	software.	The	error	bars	indicate	S.E.M.	
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Results	
Activation	of	SGK3	by	IGF1.	Stimulating	serum	starved	HEK293	cells	with	insulin-like	growth	
factor	(IGF1,	50	ng/ml)	for	10	min,	markedly	enhanced	endogenous	SGK3	kinase	activity	and	
its	T-loop	phosphorylation	(Fig	1A).	No	SGK3	activity	or	T-loop	phosphorylation	was	
observed	in	SGK3	knock-out	HEK293	cells	analysed	in	parallel,	validating	the	assay	approach	
(Fig	1A).	Consistent	with	previous	work	showing	that	both	Akt	and	SGK	phosphorylate	
NDRG1	at	Thr346	[27],	combined	treatment	with	MK-2206	Akt	inhibitor	[36]	and	14h	SGK	
inhibitor	[17,	29]	was	required	to	fully	suppress	NDRG1	phosphorylation	in	wild	type	
HEK293	cells	(Fig	1B).	In	contrast,	in	SGK3	knock-out	cells,	treatment	with	MK-2206	inhibitor	
alone	suppressed	most	of	the	NDRG1	phosphorylation	(Fig	1B).	Interestingly,	we	note	that	
addition	of	14h	and	MK2206	to	SGK3	knock	out	cells	reduces	the	low	levels	of	NDRG1	
phosphorylation	further	compared	to	MK2206	alone.	We	speculate	that	this	may	be	due	to	
low	levels	of	SGK1	activity	that	is	still	present	in	these	cells [9]	.		
	
Class	1	and	Class	3	PI3Ks	mediate	activation	of	SGK3	by	IGF1.	Time	course	analysis	revealed	
that	IGF1	increased	SGK3	activity	from	a	low	basal	level	around	3	to	4-fold	within	1	min	and	
10-fold	within	2	to	5	min.	SGK3	remained	at	a	high	level	for	up	to	8h	(Fig	2A	&	2B).	
Treatment	with	the	Class	3	PI3K	inhibitor	VPS34-IN1,	which	does	not	inhibit	Class	1	PI3K	[6],	
blocked	the	stimulation	of	SGK3	activity	and	NDRG1	phosphorylation	observed	after	1	min	
IGF1.	Between	the	2	min	to	8h	IGF1	stimulation,	VPS34-IN-1	treatment	reduced	SGK3	
activation	around	4	-fold	(Fig	2C	&	2D).	Consistent	with	VPS34-IN1	not	inhibiting	Class	1	PI-
3K,	Akt	and	its	selective	PRAS40	substrate	were	normally	phosphorylated	in	IGF1	treated	
cells	in	the	presence	of	VPS34-IN1	(Fig	2C	&	2D).		
	
In	contrast,	the	Class	1	PI3K	inhibitor	GDC-0941,	that	does	not	inhibit	hVPS34	[37],	had	no	
effect	on	basal	SGK3	activity	or	NDRG1	phosphorylation	(Fig	2E	&	F).	After	IGF1	stimulation,	
GDC-0941	appears	to	slow	the	rate	and	extent	of	activation	of	SGK3	and	NDRG1	
phosphorylation.	At	the	1-8	h	time	points	SGK3	activation	is	~2-fold	lower	(Fig	2E	&	2F).	
Marked	increase	of	NDRG1	phosphorylation	in	the	presence	of	GDC-0941	was	only	noted	at	
and	after	the	60	min	time	point.	Treatment	with	VPS34-IN1	and	GDC-0941	together	blocked	
IGF1	stimulation	of	SGK3	activity	at	all	time-points	(Fig	2G	and	2H).	We	noted	a	moderate	
stimulation	of	NDRG1	phosphorylation	at	60	min	time	point	in	the	presence	of	both	VPS34-
IN1	and	GDC-0941,	indicating	that	another	NDRG1	kinase	may	become	slowly	activated	
under	these	conditions	(Fig	2G	and	2H).	
	
SGK3	is	activated	by	insulin	and	EGF.	Stimulation	of	HEK293	cells	with	insulin	(100	nM),	
epidermal	growth	factor	(EGF,	100	ng/ml)	and	serum	(10%	[v/v])	induced	a	3	to	20-fold	
stimulation	of	SGK3	(Fig	3A).	In	contrast,	FGFbasic	(50	ng/ml),	tissue	plasminogen	activator	
(400	ng/ml)	or	H202	(1	mM)	failed	to	significantly	activate	SGK3	at	a	15	min	time	point	
despite	inducing	a	low	level	of	phosphorylation	of	NDRG1.	FGFbasic	also	induced	a	marked	
activation	of	ERK1/ERK2	(Fig	3A).	
	
Oncogenic	Ras,	ERBB2	and	EGFR	activate	SGK3.	We	transiently	transfected	HEK293	cells	
with	KRAS[G12C],	KRAS[G12D],	NRAS[G12D],	ERB2[V842I]	and	EGFR[L833R]	oncogenes	
under	conditions	where	80%	of	cells	were	transfected	and	measured	the	effect	that	this	had	
on	endogenously	expressed	SGK3.	This	revealed	that	all	oncogenes	tested,	stimulated	SGK3	
activity	2-5-fold	and	enhanced	NDRG1,	Akt	and	ERK	phosphorylation	(Fig	3B).	Strikingly,	
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VPS34-IN1	had	no	significant	effect	on	SGK3	activation	or	NDRG1	phosphorylation	induced	
by	overexpression	of	oncogenic	KRAS,	which	was	instead	blocked	by	GDC-0941	(Fig	3C).	This	
suggests	that	oncogenic	KRAS	is	activating	SGK3	through	the	PI3K	pathway	rather	than	
hVPS34.	
	
IGF1	enhances	endosomal	PtdIns(3)P.	To	assess	intracellular	levels	of	PtdIns(3)P,	we	used	a	
previously	described	method	[32],	in	which	cells	were	fixed	with	formaldehyde	and	then	
exposed	to	a	combination	of	recombinant	wild	type	PtdIns(3)P-binding	region	of	the	
HRS2xFYVE	conjugated	to	Alexa	Fluor-488	(green	dye	labelled)	and	the	non-PtdIns(3)P-
binding	point	mutant	of	this	FYVE	domain	conjugated	to	Alexa	fluor-594	(red	dye	labelled).	
The	levels	of	green	and	red	probe	remaining	associated	with	cell	structures	resembling	
endosomes	after	washing	was	used	to	assess	endosomal	levels	of	PtdIns(3)P	(Fig	4).	These	
experiments	revealed	that	in	wild	type	serum	starved	cells	consistent	with	previous	work	
[32],	the	wild	type	PtdIns(3)P-binding	HRS2xFYVE	probe	associated	with	punctate	structures	
resembling	endosomes,	whilst	localisation	of	the	non-PtdIns(3)P	binding	probe	was	more	
diffuse	and	consistent	with	background	binding	(Fig	4,	compare	upper	and	lower	panels).	
We	observed	10	min	IGF1	stimulation	increased	~2-fold	the	number	of	punctate	structures	
in	3	separate	experiments	(compare	Fig	4A,4C,4I).	Treatment	with	VPS34-IN1	had	a	marked	
effect	and	reduced	the	number	of	punctate	structures	and	the	amount	of	staining	
associated	with	each	cell	around	3-fold	(Fig	4E,	4I),	GDC-0941	only	had	a	moderate	effect	on	
reducing	binding	of	the	PtdIns	3P-probe	to	endosome	structures	(Fig	4G,	4I).	IGF1	
stimulation	had	no	effect	on	binding	of	the	mutant	probe	in	the	red	channel	(Fig	4B,4D,	4F,	
4H).	
	
IGF1	enhances	endosomal	localisation	of	SGK3	via	hVPS34.	To	investigate	localisation	of	
endogenous	SGK3	in	HEK293	cells,	we	deployed	a	CRISPR/CAS9	approach	to	homozygously	
knock-in	a	GFP	tag	onto	the	C-terminus	of	SGK3.	The	resultant	fusion	protein	is	expressed	at	
a	similar	level	to	non-tagged	SGK3	in	wild	type	cells	(Fig	S1A).	GFP	immunofluorescence	
analysis	of	serum	starved	cells	revealed	that	a	significant	proportion	of	SGK3-GFP	was	co-
localised	with	the	EEA1	endosomal	marker	and	located	in	punctate	structures	(Fig	4J	&	4K).	
Stimulation	with	IGF1	for	10	min	induced	~2-fold	increase	in	endosomal	localisation	of	
SGK3-GFP	with	EEA1	in	3	independent	experiments	(Fig4L,	4M,	4R).	Treatment	with	VPS34-
IN1,	significantly	reduced	endosomal	localisation	of	SGK3-GFP	(Fig	4N,	4O,	4R).	The	
structurally	unrelated	hVPS34	inhibitor	termed	SAR405	[38],	also	blocked	endosomal	
localisation	of	SGK3-GFP	(Fig	S1B).	GDC-0941	had	no	significant	effect	on	SGK3-GFP	
endosomal	localisation	(Fig	4P,	4Q,	4R).	
	
IGF1	does	not	affect	endosomal	localisation	or	activity	of	hVPS34.	To	better	study	the	
hVPS34	complex,	we	employed	a	CRISPR/CAS9	approach	to	generate	homozygous	knock-in	
mutations	in	which	GFP	was	fused	to	the	hVPS34	catalytic	subunit	(N-terminus)	as	well	as	
the	UV-RAG	subunit	(C-terminus).	The	fusion	protein	was	expressed	at	a	similar	level	to	that	
of	non-tagged	protein	in	wild	type	cells	(Fig	5A).	Endogenous	GFP-VPS34	and	GFP-UV-RAG	
co-localised	with	EEA1	at	the	endosome	in	serum	starved	cells	(Fig	6).	Stimulation	with	IGF1	
for	15	minutes	did	not	significantly	alter	endosomal	localisation	of	hVPS34	or	UV-RAG.	
VPS34-IN1	treatment,	however,	induced	a	change	in	morphology	of	EEA1	and	GFP-VPS34	
(Fig	6E,	6F),	and	GFP-UV-RAG	(Fig	6N,6O)	associated	endosomal	structures.	GDC-0941	had	
no	effect	on	localisation	of	any	hVPS34	component	(Fig	6G,	6H,	6P,	6Q).		
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We	also	immunoprecipitated	endogenous	GFP	tagged	hVPS34	and	UV-RAG	employing	the	
high	affinity	GFP	“Trap”	antibodies.	Immunoblot	analysis	confirmed	that	similar	levels	of	
Beclin-1	and	UV-RAG	were	immunoprecipitated	with	GFP-hVPS34	and	GFP-UV-RAG	(Fig	5B).	
We	consistently	observed	around	3-fold	higher	levels	of	hVPS34	and	VPS15	were	co-
immunoprecipitated	with	GFP-VPS34	compared	to	GFP-UV-RAG.	The	immunoprecipitates	
were	subjected	to	a	PI3-kinase	assay	and	formation	of	32P-PtdIns(3)P	assessed	by	thin	layer	
chromatography	and	autoradiography.	As	expected,	when	GFP	immunoprecipitations	were	
undertaken	from	wild	type	HEK293	cells	not	expressing	GFP	tagged	hVPS34	subunits,	no	PI3-
kinase	activity	was	detected	(Fig	5B).	Significant	PI3K	activity	was	detected	in	the	
immunoprecipitates	derived	from	GFP-VPS34	and	GFP-UV-RAG	that	was	sensitive	to	VPS34-
IN1	(Fig	5B).	Stimulation	of	cells	with	IGF1,	conditions	that	activate	SGK3	over	10-fold,	did	
not	significantly	affect	PI3K	activity	measured	in	our	assays	(Fig	5B).		
	
Evidence	that	the	UV-RAG	complex	plays	a	role	in	IGF1	induced	activation	of	SGK3.	To	
study	the	impact	that	knock-down	of	VPS34	or	UV-RAG	had	on	SGK3	activity,	we	employed	
a	recently	described	method	termed	Affinity	Directed	Protein	Missile	System	(AdPROM)	[34,	
39]	to	induce	ubiquitylation	and	proteasome	mediated	degradation	of	GFP	epitope	tagged	
proteins.	This	approach	involves	use	of	retroviral	overexpression	of	the	VHL1	E3	ligase	fused	
to	an	anti-GFP	nanobody-16	(VHL-aGFP16),	that	binds	and	induces	degradation	of	GFP	
fusion	knock-in	proteins.	Our	control	cells	only	expressed	the	anti-GFP	nanobody-16	
(aGFP16)	(Fig	7).	We	overexpressed	VHL-aGFP16	in	the	GFP-VPS34	and	GFP-UV-RAG	knock-
in	HEK293	cells,	which	induced	~90%	knock-down	of	hVPS34	(Fig	7A)	or	UV-RAG	(Fig	7B).	
Knock-down	of	hVPS34	also	reduced	expression	Beclin-1,	VPS15,	and	UV-RAG	(Fig	7A).	
Knock-down	of	UV-RAG	had	no	marked	effect	on	hVPS34	expression,	but	reduced	levels	of	
Beclin-1	and	VPS15	(Fig	7B).	Our	studies	reveal	that	reducing	expression	of	either	hVPS34	or	
UV-RAG	by	over	90%,	partially	inhibited	IGF1	induced	activation	of	SGK3	(Fig	7A,	7B).	A	
similar	reduction	of	SGK3	was	observed	in	the	UV-RAG	knockdown	compared	to	VPS34	
knock-down	(Fig	7A,	7B).	The	reduced	SGK3	activity	in	these	cells	could	be	further	inhibited	
by	VPS34-IN1	indicating	that	low	levels	of	VPS34	complex	still	present	still	contributes	
towards	SGK3	activity	(Fig	7A,	7B).		
	
Role	that	SHIP2	plays	in	regulating	IGF1	induced	activation	of	SGK3.	As	described	in	the	
introduction,	PtdIns(3)P	can	be	generated	in	a	hVPS34	independent	manner	by	metabolism	
of	PtdIns(3,4,5)P3	to	PtdIns(3,4)P2	via	the	SHIP2	phosphatase	and	then	to	PtdIns(3)P	by	
INPP4A/B	[40].	To	explore	the	contribution	that	this	pathway	plays	in	controlling	SGK3	
activity,	we	generated	SHIP2	knock-out	HEK293	cells	by	CRISPR/Cas9	methodology	and	
measured	PtdIns(3,4,5)P3	and	PtdIns(3,4)P2	levels	by	an	HPLC	method.	This	revealed	that,	in	
response	to	IGF1	stimulation,	five	different	species	of	PtdIns(3,4,5)P3	could	be	measured	
that	were	all	elevated	2	to	3-fold	in	the	SHIP2	knock-out	cells	at	5,	15	and	60	min	following	
IGF1	stimulation	(Fig	8A).	The	one	species	of	PtdIns(3,4)P2	that	could	be	measured	was	only	
modestly	elevated	following	5	min	IGF1	stimulation,	and	did	not	differ	significantly	between	
the	wild	type	and	SHIP2	knock-out	cell	lines	(Fig	8B).		
	
We	next	measured	SGK3	and	Akt	kinase	activity	in	the	wild	type	and	SHIP2	knock-out	cells.	
After	5	min	IGF1	stimulation,	despite	PtdIns(3,4,5)P3	being	elevated	in	SHIP2	knock-out	cells,	
SGK3	activity	and	T-loop	phosphorylation	was	reduced	~2-fold	compared	to	wild	type	cells	
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(Fig	8C).	Treatment	of	wild	type	but	not	SHIP2	knock-out	cells	with	the	AS1938909	SHIP2	
inhibitor	[41],	also	reduced	SGK3	activity	~2-fold	(Fig	8C).	In	contrast,	consistent	with	
elevated	PtdIns(3,4,5)P3,	Akt	activity	and	Thr308	phosphorylation	was	enhanced	in	the	SHIP2	
knock-out	cells	(Fig	8D).	Re-introducing	SHIP2	into	knock-out	cells,	restored	activation	of	
SGK3	and	T-loop	phosphorylation,	to	a	similar	extent	as	observed	in	the	wild	type	cells	at	
the	5	min	time	point	of	IGF1	stimulation	(Fig	8E).	At	longer	time	point	of	60	min	SHIP2	
knock-out	did	not	affect	the	degree	of	activation	of	SGK3	(Fig	8E).	We	also	observed	that	in	
SHIP2	knock-out	cells,	after	5	min	IGF1	stimulation	when	PtdIns(3,4,5)P3	levels	are	elevated	
(Fig	8A),	GDC-0941	still	reduces	SGK3	activity	to	near	basal	levels	(Fig	8F).	This	observation	
could	be	accounted	for	by	a	model	in	which	PtdIns(3,4,5)P3	promotes	SGK3	activity	by	
stimulating	mTORC2	and/or	by	other	inositol	phosphatases	converting	PtdIns(3,4,5)P3	to	
PtdIns(3)P.	
	
To	further	explore	the	possibility	that	mTORC2	is	involved	in	activating	SGK3	by	IGF1,	we	
generated	a	CRISPR/CAS9	mediated	knock	out	of	the	SIN1	subunit	of	mTORC2	in	HEK	293	
cells.	We	observed	that	loss	of	mTORC2	activity	due	to	knocking	out	SIN1,	also	strikingly	
ablates	SGK3	activitation	by	IGF1	(Fig	9).	As	a	control,	we	also	show	that	deletion	of	SIN1	
also	abolishes	Akt	phosphorylation	at	Ser473	(Fig	9).	These	results	are	consistent	with	a	
previous	study	where	it	was	demonstrated	that	siRNA	knock-down	of	Rictor	subunit	of	
mTORC2	in	ZR751	breast	cancer	cells,	also	inhibited	SGK3	activity [17].	
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Discussion	
We	demonstrate	that	various	growth	factors	including	IGF1	and	EGF	as	well	as	insulin	
activate	SGK3.	Inhibiting	either	Class	1	or	Class	3	PI3K	with	selective	inhibitors	partially	
reduces	SGK3	activity.	A	combination	of	these	inhibitors	is	needed	to	ablate	SGK3	activity.	
The	inhibitors	used	GDC-0941	(Class	1	PI3K) [37]	and	VPS34-IN1	(Class	3	PI3K) [6]	are	highly	
selective	and	do	not	inhibit	Class	2	PI3-kinases,	indicating	that	these	do	not	play	a	major	role	
in	controlling	growth	factor	mediated	activation	of	SGK3.	These	results	establish	that	both	
Class	1	and	Class	3	PI3K	pathways	are	need	to	maximally	activate	SGK3.	However,	after	
inhibiting	either	Class	1	or	Class	3	PI3K,	the	remaining	20-40%	SGK3	activity	is	still	sufficient	
to	phosphorylate	NDRG1	to	almost	the	same	extent	as	in	the	absence	of	inhibitors	(Fig	2).	It	
is	possible	that	there	are	physiological	situations	or	stresses	that	lead	to	the	inhibition	of	
Class	1	or	Class	3	PI3K	pathways,	in	which	SGK3	has	evolved	to	remain	active	whenever	one	
of	these	pathways	is	substantially	suppressed.	
	
To	investigate	how	IGF1	controls	PtdIns(3)P	levels	we	studied	localisation	of	endogenous	
knock-in	GFP-SGK3	and	monitored	binding	of	the	HRS2xFYVE	PtdIns(3)P	binding	probe	to	
permeabilised	fixed	cells	(Fig	4).	We	found	that	IGF1	induced	around	2-fold	increase	in	
endosomal	PtdIns(3)P	in	a	manner	that	was	blocked	with	hVPS34.	This	is	consistent	with	
IGF1	activating	SGK3	by	enhancing	endosomal	PtdIns(3)P	levels	by	stimulating	the	activity	of	
hVPS34.	Earlier	studies	have	also	reported	that	insulin	moderately	enhances	PtdIns(3)P	
levels	in	adipocytes,	myocytes,	fibroblasts	and	hepatocytes	[42-45].	We	observed	that	
PtdIns(3)P,	even	after	stimulation	with	IGF1,	was	mainly	localised	to	endosomal	structures	
and	not	observed	at	the	plasma	membrane,	findings	consistent	with	most	previous	work	[6,	
46-48].	However,	treatment	with	the	PI3K	Class	I	inhibitor	GDC0941	did	induce	a	~2	fold	
reduction	in	total	PI(3)P	levels	in	cells.	It	should	be	noted	that	one	study	reported	insulin	
increased	PtdIns(3)P	in	the	plasma	membrane	in	adipocytes	[42]	and	another	at	
lamellipodia	[45],	based	on	the	use	of	the	same	HRS2xFYVE	probe	utilised	in	our	work.	
However,	we	are	not	able	to	confirm	these	results	in	HEK293	cells	analysed	under	
conditions	in	which	SGK3	is	activated	via	the	hVPS34	pathway.	To	more	easily	study	the	
intracellular	localisation	and	immunoprecipitate	endogenous	hVPS34	complex,	we	
generated	knock-in	mutations	in	which	hVPS34	or	UV-Rag	were	endogenously	tagged	with	
GFP.	Localisation	studies	confirmed	that	hVPS34	and	its	regulatory	UV-RAG	subunit	are	
localised	at	the	endosomal	membranes,	consistent	with	much	previous	work	[49,	50].	
Following	IGF1	stimulation,	we	did	not	observe	obvious	spatial	changes	in	the	endosomal	
localisation	of	hVPS34	or	UV-RAG	components.	This	does	not	rule	out	that	there	is	a	small,	
spatially-restricted	pool	of	IGF1-regulated	PtdIns(3)P	and	hVPS34-UV-Rag	complex,	that	is	
targeted	to	discrete	mirco-domains	that	cannot	be	resolved	by	the	analysis	that	we	have	
undertaken.	
	
Following	immunoprecipitation	of	endogenous	GFP-VPS34	or	GFP-UV-RAG,	we	observed	
PI3K	activity	that	could	be	inhibited	with	VPS34-IN1.	However,	following	IGF1	stimulation	
we	did	not	observe	stimulation	of	PI3K	activity	in	our	immunoprecipitation	experiments.	It	is	
possible	that	only	a	small	localised	pool	of	hVPS34	is	activated	by	IGF1,	that	cannot	be	
measured	over	the	background	of	total	hVPS34	activity	that	was	immunoprecipitated.	We	
also	cannot	rule	out	that	the	IGF1-activated	pool	of	hVPS34	in	cells	may	not	be	stable	to	
immunoprecipitation	or	that	a	factor	required	for	activation	is	missing	in	our	in	vitro	assays.	
One	previous	study	reported	after	immunoprecipitation	of	the	UV-RAG	complex	of	VPS34	
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from	insulin	stimulated	primary	hepatocytes,	that	a	1.4-fold	increase	in	PI3K	activity	was	
observed	after	30	min	that	increased	to	2-fold	after	60	min	insulin	stimulation	[44].	The	
reported	activation	of	UV-RAG	immunoprecipitated	PI3K	activity	observed	in	this	study	was	
much	slower	than	the	time	course	that	IGF1	enhances	SGK3	maximally	within	2-5	min.	We	
immunoprecipitated	the	UV-RAG	complex	in	7	separate	experiments	and	failed	to	observe	a	
significant	stimulation	of	activity	even	at	the	60	min	time	point	(Fig	5).		
	
As	knock-down	of	the	UV-RAG	subunit	of	hVPS34	complex	induces	the	same	loss	of	SGK3	
activity	than	the	equivalent	knock-down	of	hVPS34	(Fig	7),	we	conclude	that	the	UV-RAG	
complex	of	hVPS34	plays	a	role	in	controlling	IGF1	stimulation	of	SGK3.	We	observe	that	
around	90%	knock-down	of	hVPS34	or	UV-RAG	only	partially	reduces	SGK3	activity	
(compared	to	treatment	with	hVPS34	inhibitor),	emphasising	the	high	sensitivity	of	the	
system	and	that	only	a	small	proportion	of	the	total	VPS34/UV-RAG	complex	is	required	to	
activate	SGK3.	This	further	highlight	how	SGK3	may	have	evolved	to	counteract	inhibition	of	
Class	3	PI3K	and	remain	active	under	conditions	where	hVPS34	is	substantially	inhibited.	
Further	work	is	required	to	establish	how	growth	factors	regulate	the	activity	and/or	
localisation	the	UV-RAG	complex	of	hVPS34	to	enhance	PtdIns(3)P	levels	and	hence	SGK3	
activity.	In	this	regard,	previous	studies	have	noted	that	UV-RAG	is	phosphorylated	by	
mTORC1	[32,	51]	and	possibly	Akt	[52].	It	would	be	interesting	to	explore	whether	
phosphorylation	of	UV-RAG	contributed	to	the	mechanism	by	which	growth	factors	
stimulate	hVPS34.	
	
Regarding	the	mechanism	by	which	Class	1	PI3K	controls	SGK3,	our	data	is	in	agreement	
with	previous	work	[6,	40],	indicating	that	PtdIns(3,4,5)P3	generated	through	activation	of	
Class	1	PI3K	is	converted	to	PtdIns(3)P	via	the	sequential	actions	of	inositol	phosphatases	
SHIP2	[14]	and	phosphatidylinositol	4-phosphatases	(INPP4A/B)	[15].	Knock-out	or	inhibition	
of	SHIP2	that	would	be	expected	to	lower	the	level	of	PtdIns(3)P	resulting	from	
dephosphorylation	of	PtdIns(3,4,5)P3	and	therefore	reduce	SGK3	activity,	which	is	what	we	
observe	at	an	early	5	min	IGF1	treatment	time	point	(Fig	8).	It	is	well	established	that	
PtdIns(3,4,5)P3	and	PtdIns(3,4)P2	are	mainly	located	within	the	plasma	membrane	where	
Class	1	PI3K	is	activated [48,	53].	We	would	therefore	expect	that	the	pool	of	PtdIns(3)P	
generated	through	dephosphorylation	of	PtdIns(3,4,5)P2	would	also	reside	on	the	plasma	
membrane.	However,	we	were	unable	to	visualise	significant	PtdIns(3)P	or	SGK3	at	the	
plasma	membrane,	even	after	IGF1	stimulation	(Fig	4).	The	reasons	for	this	are	not	clear	and	
could	arise	from	plasma	membrane	concentrations	of	PtdIns(3)P	or	GFP-SGK3	being	too	low	
or	transient	to	detect	using	the	technology	we	are	deploying.	Other	groups	have	also	
reported	that	SGK3	resides	at	the	endosome	and	cannot	be	visualised	at	the	plasma	
membrane [40, 54].	We	cannot	rule	out	that	PtdIns(3)P	produced	by	from	
dephosphorylation	of	PtdIns(3,4,5)P3	is	somehow	localised	elsewhere	in	cells	rather	than	
the	plasma	membrane	resulting	from	some	unknown	membrane	trafficking	pathway.	In	this	
regard,	we	noted	that	treatment	of	cells	with	the	Class	1	PI3K	inhibitor	GDC-0941	
moderately	reduced	the	signal	from	the	HRS2xFYVE	probe	(Fig	4I).	Future	work	is	required	
to	address	where	PtdIns(3)P	produced	from	the	dephosphorylation	of	PtdIns(3,4,5)P3	
resides	and	activates	SGK3.	
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Class	1	PI3K	is	thought	to	also	contribute	to	the	activation	of	mTORC2	[55],	with	one	study	
suggesting	that	this	is	mediated	through	PtdIns(3,4,5)P3-binding	to	the	PH	domain	of	the	
SIN1	component	of	mTORC2	[56].	Stimulation	of	mTORC2	activity	through	Class	1	PI3K	
would	also	be	expected	to	lead	to	hydrophobic	motif	phosphorylation	of	SGK3	triggering	it	
to	be	activated	by	PDK1 [5].	This	could	represent	a	third	upstream	pathway	by	which	SGK3	
activity	is	controlled.	Our	observations	that	Class	1	PI3K	inhibitors	still	suppress	SGK3	
activity	in	SHIP2	knock-out	cells	that	have	elevated	PtdIns(3,4,5)P3	levels,	support	a	model	in	
which	Class	1	PI3K	is	promoting	mTORC2	to	activate	SGK3.	However,	we	cannot	rule	out	
that	in	the	SHIP2	knockout	cells,	other	inositol	phosphatases	convert	PtdIns(3,4,5)P3	to	
PtdIns(3)P,	explaining	why	Class	1	inhibitors	still	supress	SGK3	activity.	Oncogenic	Ras	is	well	
known	to	activate	Class	1	PI3K	[57],	but	there	are	no	reports	on	whether	it	is	also	capable	of	
activating	Class	3	PI3K.	We	find	that	overexpression	of	oncogenic	Ras	leads	to	activation	of	
SGK3,	that	unlike	IGF1	stimulation,	is	entirely	inhibited	by	treatment	with	Class	1	PI3K	
inhibitors.	This	demonstrates	that	oncogenic	Ras	in	contrast	to	growth	factors	is	unable	to	
activate	Class	3	PI3K	and	emphasises	that	activation	of	SGK3	could	contribute	to	Ras	driven	
tumour	biology.		
	
In	summary,	we	demonstrate	that	in	response	to	growth	factors	such	as	IGF1,	three	
upstream	pathways	contribute	to	SGK3	activity	(Fig	9).	Firstly,	IGF1	stimulates	production	of	
endosomal	PtdIns(3)P	likely	through	the	UV-RAG	VPS34	complex,	thereby	recruiting	SGK3	to	
endosomes	where	it	is	activated.	More	work	is	needed	to	define	the	mechanism	by	which	
IGF1	controls	the	UV-RAG	complex	of	hVPS34.	Secondly,	Class	1	PI3K	stimulates	SGK3	
through	enhanced	production	of	PtdIns(3)P	resulting	from	dephosphorylation	of	
PtdIns(3,4,5)P3.	Additional	work	is	needed	to	define	where	the	PtdIns(3)P	produced	through	
this	pathway	resides,	and	why	it	cannot	be	visualised	on	the	plasma	membrane.	Thirdly,	our	
data	are	consistent	with	a	model	in	which	PtdIns(3,4,5)P3	produced	from	activation	of	Class	
1	PI3K,	promotes	phosphorylation	of	the	hydrophobic	motif	of	SGK3	by	mTORC2,	thereby	
stimulating	activation	of	SGK3	by	PDK1.	The	results	presented	in	this	study	emphasise	the	
diverse	pathways	that	exist	in	cells	to	activate	SGK3	in	vivo.	They	also	illustrate	how	SGK3	is	
well	placed	to	remain	substantially	active	and	counteract	physiological	conditions	or	
stresses	that	lead	to	the	inhibition	of	either	Class	1	or	Class	3	PI3K	pathways.		
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Figure	Legends	
	
Figure	1	–	SGK3	is	activated	by	IGF1	(A)	Wild	type	(WT)	and	SGK3	knock0out	(KO)	HEK293	
cells	were	serum	starved	for	16	hours	prior	to	stimulation	with	or	without	50	ng/ml	IGF1	for	
10	minutes.	Subsequently,	cells	were	lysed	and	endogenous	SGK3	immunoprecipitated	with	
anti-SGK3	antibody.	Immunoprecipitates	were	assayed	for	SGK3	kinase	activity	by	
measuring	phosphorylation	of	the	Crosstide	substrate	peptide	in	the	presence	of	0.1	mM	
32PgATP	in	a	30	min	reaction.	The	lysates	and	immunoprecipitates	were	subjected	to	
immunoblot	analysis	with	the	indicated	antibodies	following	the	kinase	assay.	Kinase	
reactions	are	presented	as	means	±	SEM	for	triplicate	reactions.	Similar	results	were	
obtained	in	at	least	two	independent	experiments.	(B)	As	in	(A)	except	cells	were	treated	
with	or	without	3	µM	14H	and/or	1	µM	MK2206	for	1	hour	before	stimulation	with	or	
without	50	ng/ml	IGF1	for	10	minutes.	Cell	lysates	were	subjected	to	immunoblot	analysis	
with	the	indicated	antibodies.	
	
Figure	2	–Class	1	and	Class	3	PI3Ks	mediate	IGF1	induced	SGK3	activity.	HEK293	cells	were	
serum	starved	for	16	hours.	1	hour	Prior	to	stimulation	cells	were	left	untreated	(A	&	B)	or	
treated	with	1	µM	VPS34-IN1	(C	&	D)	or	0.5	µM	GDC-0941	(E	&	F)	or	1	µM	VPS34-IN1	and	
0.5	µM	GDC-0941	(G	&	H	).	Cells	were	then	stimulated	with	50	ng/ml	IGF1	for	the	indicated	
times	in	presence	of	inhibitors.	Cells	were	lysed	and	endogenous	SGK3	immunoprecipitated	
with	anti-SGK3	antibody.	The	lysates	and	immunoprecipitates	were	subjected	to	
immunoblot	analysis	with	the	indicated	antibodies,	after	being	assayed	for	SGK3	kinase	
activity	by	measuring	phosphorylation	of	the	Crosstide	substrate	peptide	in	the	presence	of	
0.1	mM	32PgATP	in	a	30	min	reaction.	Kinase	reactions	are	presented	as	means	±	SEM	for	
triplicate	reactions.	Similar	results	were	obtained	in	at	least	two	independent	experiments	
for	all	data	shown.	
	
Figure	3	–	SGK3	activity	is	induced	by	growth	factors,	insulin	and	oncogenic	Ras.	(A)	
HEK293	cells	were	serum	starved	for	16	hours	prior	to	stimulation	with	or	without	the	
indicated	concentrations	of	IGF1,	EGF,	insulin,	FGF,	TPA,	H202	and	serum	for	15	minutes.	
Endogenous	SGK3	was	immunoprecipitated	from	the	lysates	and	SGK3	kinase	activity	
assessed	by	measuring	phosphorylation	of	the	Crosstide	substrate	peptide	in	the	presence	
of	0.1	mM	32PgATP	in	a	30	min	reaction.	Both	immunoprecipitates	and	lysates	were	
subjected	to	western	blotting	with	the	indicated	antibodies.	(B)	As	in	(A)	except	that	HEK293	
cells	were	transiently	transfected	when	60%	confluent,	with	KRAS[G12C],	KRAS[G12D],	
NRAS[G12D],	ERBB2[V842I]	and	EGFR[L833R]	(All	HA	epitope	tagged).	48	hours	later,	WT	
and	transfected	cells	were	serum	starved	got	16	h	before	cells	lysed	without	further	
stimulation.	(C)	As	in	(B)	except	that	HEK293	cells	were	transiently	transfected	with	
KRAS[G12C]	and	KRAS[G12D]	and	treated	as	indicated	with	VPS34-IN1	(1µM)	and	/or	GDC-
0941	(0.5	µM)	prior	to	stimulation	with	50	ng/ml	IGF1	for	10	min.	Kinase	reactions	are	
presented	as	means	±	SEM	for	triplicate	reactions.	Similar	results	were	obtained	in	at	least	
two	independent	experiments	for	all	data	shown.	
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Figure	4	–	IGF1	stimulation	enhances	endosomal	PtdIns(3)P	and	recruitment	of	GFP-SGK3	
to	the	endosomes.	HEK293	cells	were	serum	starved	overnight	then	treated	as	indicated	
with	or	without	VPS34-IN1	(1µM)	and	/or	GDC-0941	(0.5	µM)	for	60	minutes	prior	to	
stimulation	with	50	ng/ml	IGF1	for	15	minutes.	Cells	were	subsequently	fixed	with	4%	(v/v)	
paraformaldehyde	and	stained	with	recombinant	wild	type	(WT)	PtdIns(3)P	binding	probe	
FYVE	domain	of	HRS[147-223]	conjugated	to	Alexa	Fluor-488	conjugate	(green	channel)	(A,	
C,	E,	G)	or	with	the	mutant	non-PtdIns(3)P	binding	FYVE	domain	of	HRS[147-223,	
H176A/H177A]	(red	channel,	Alexa	594).	(B,	D,	F,	H).	(I)	The	histogram	displays	a	
representative	quantitation	of	the	sum	fluorescence	intensity	of	PX	domain	staining	on	
endosomal	structures	±	S.E.M	(increase	in	PtdIns(3)P	levels	upon	IGF1	stimulation	ranged	
from	30-50%	compared	to	serum	starved	cells).	(J	–	Q)	GFP-SGK3	knock-in	HEK293	cells	
were	serum	starved	overnight	and	treated	as	above	prior	to	IGF1	stimulation.	Cells	were	
fixed	with	4%	(v/v)	paraformaldehyde	and	GFP	distribution	visualized	using	chicken	anti-GFP	
primary	and	anti-chicken	Alexa	Fluor-488	to	enhance	the	GFP	signal	(upper	panel).	SGK3	co-
localisation	with	the	early	endosomal	marker	EEA1,	was	visualized	using	rabbit	anti-EEA1	
primary	and	anti-rabbit	Alexa	Fluor-594	secondary	antibody	(lower	panel).	(R)	The	
histogram	displays	a	representative	quantitation	of	the	sum	of	intensity	of	fluorescent	signal	
from	GFP-SGK3,	co-localising	with	the	EEA1	marker	at	the	endosomes	±S.E.M	following	the	
various	treatments	(increase	in	GFP-SGK3	levels	at	the	endosomes	ranged	from	30-60%	
upon	addition	of	IGF1	compared	to	serum	starved	conditions).		
	
Figure	5	–	IGF1	does	not	stimulate	hVPS34	activity.	Wild	type	(WT),	GFP-Vps34	or	GFP-UV-
RAG	knock-in	HEK293	cells	were	cultured	in	serum	lysed	and	subjected	to	immunoblot	
analysis	with	the	indicated	antibodies.	(B)	Wild	type	(WT),	GFP-Vps34	or	GFP-UV-RAG	
knock-in	HEK293	cells	were	serum	starved	overnight	prior	to	treatment	with	or	without	50	
ng/ml	IGF1	for	15	min.	Cells	were	subsequently	lysed	using	a	1%	(v/v)	NP-40	lysis	buffer	and	
immunoprecipitations	undertaken	using	GFP-TRAP	antibodies.	The	immunoprecipitates	
were	subjected	to	a	kinase	assays	in	the	presence	of	PtdIns	(5	µg),	0.1	mM	32PgATP	for	a	30	
min	reaction	measure	in	the	absence	or	presence	VPS43-IN1	(1	µM)	as	indicated.	Reactions	
were	chromatographed	on	a	Silica	60	TLC	plate	and	32P-radioactivity	associated	with	the	
spot,	corresponding	to	PtdIns(3)P,	was	visualized	by	autoradiography	and	quantified	by	
Cerenkov	scintillation.	Immunoprecipitates	were	also	subjected	to	immunoblot	analysis	with	
the	indicated	antibodies.	In	the	top	panel	we	show	the	quantitation	of	the	VPS34	PI	3-kinase	
activity.		The	data	is	presented	as	means	±	SEM	for	triplicate	reactions.	Similar	results	were	
obtained	in	at	least	two	independent	experiments	for	all	data	shown.	
	
Figure	6	–IGF1	does	not	affect	localisation	of	hVPS34	and	UV-RAG.	GFP-Vps34	(A	to	I)	or	
GFP-UV-RAG	(J	to	R)	knock-in	HEK293	cells	were	serum	starved	overnight	and	treated	as	
indicated	with	or	without	VPS34-IN1	(1µM)	and	/or	GDC-0941	(0.5	µM)	for	60	minutes	prior	
to	stimulation	with	IGF1	for	15	minutes.	Cells	were	subsequently	fixed	with	4%	(v/v)	
paraformaldehyde	and	GFP	distribution	visualized	using	chicken	anti-GFP	primary	and	anti-
chicken	Alexa	Fluor-488	to	enhance	the	GFP	signal.	Co-localisation	of	hVPS34	or	UV-RAG	
with	early	endosomal	EEA1	marker	was	visualized	using	rabbit	anti-EEA1	primary	and	anti-
rabbit	Alexa	Fluor-594	secondary	antibody.	The	histograms	display	quantitation	of	the	sum	
of	intensity	of	fluorescent	signal	from	GFP-Vps34	(I)	or	GFP-UV-RAG	(R),	co-localising	with	
the	EEA1	marker	±S.E.M	following	the	various	treatments.		
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Figure	7	–AdPROM	mediated	knockdown	of	hVPS34	and	UV-RAG	reduces	IGF1	induced	
SGK3	activation.	GFP-Vps34	(A)	or	GFP-UV-RAG	(B)	knock-in	HEK293	cells	that	stably	
express	either	the	anti-GFP	nanobody	(Control-aGFP16)	or	the	VHL-E3-ligase	–anti-GFP-
nanobody	(VHL-aGFP16)	were	generated	as	described	in	the	Materials	and	methods.	Cells	
were	serum	starved	overnight	and	treated	as	indicated	with	or	without	VPS34-IN1	(1µM)	
and	/or	GDC-0941	(0.5	µM)	for	60	minutes	prior	to	stimulation	with	50	ng/ml	IGF1	for	15	
min.	Endogenous	SGK3	was	immunoprecipitated	from	cell	lysates	and	kinase	activity	
assessed	by	measuring	phosphorylation	of	the	Crosstide	substrate	peptide	in	the	presence	
of	0.1	mM	32PgATP	in	a	30	min	reaction.	Both	immunoprecipitates	and	lysates	were	
subjected	to	western	blotting	with	the	indicated	antibodies.	Kinase	reactions	are	presented	
as	means	±	SEM	for	triplicate	reactions.	Similar	results	were	obtained	in	at	least	two	
independent	experiments	for	all	data	shown.	
	
Figure	8	–	SHIP2	regulates	SGK3	activity.	(A	&	B)	Wild	type	(WT)	or	SHIP2	knock-out	(KO)	
cells	were	serum	starved	overnight	and	stimulated	with	50	ng/ml	IGF1	stimulation	for	the	
indicated	time	points.	Cells	were	scraped	into	0.1	M	HCl	and	snap	frozen.	PtdIns(3,4,5)P3	(A)	
and	PtdIns(3,4)P2	(B)	levels	were	determined.	The	data	is	presented	for	a	total	of	5	separate	
species	of	PtdIns(3,4,5)P3	that	were	measured.	One	species	of	PtdIns(3,4)P2	was	measured.	
(C)	as	in	(A)	except	that	cells	were	treated	in	the	absence	and	presence	of	the	SHIP2	
inhibitor	AS1938909	(10	µM)	for	1	hour	prior	to	stimulation	with	IGF1.	Endogenous	SGK3	
was	immunoprecipitated	from	cell	lysates	with	anti-SGK3	antibody	and	immunoprecipitates	
subjected	to	an	SGK3	kinase	activity	assay	by	measuring	phosphorylation	of	the	Crosstide	
substrate	peptide	in	the	presence	of	0.1	mM	32PgATP	in	a	30	min	reaction.	Immunoblot	
analysis	was	also	carried	out	on	the	immunoprecipitates,	using	the	indicated	antibodies	(D)	
As	in	(A)	except	that	Akt	kinase	activity	was	assayed	by	measuring	phosphorylation	of	the	
Crosstide	substrate	peptide	in	the	presence	of	0.1	mM	32PgATP	in	a	30	min	reaction.	Akt	
immunoprecipitates	were	subjected	to	immunoblot	analysis	with	the	indicated	antibodies.	
(E)	As	in	(A)	except	that	HA-SHIP2	was	re-expressed	in	the	SHIP2	knock-out	(SHIP2	rescue)	as	
described	in	the	Materials	and	Methods.	Wild	type,	SHIP2	KO	and	SHIP2	Rescue	cell	lysates	
were	immunoblotted	with	SHIP2	antibody	to	demonstrate	SHIP2	knock	out	and	rescue	in	
comparison	to	WT.	(F)	As	in	(A)	except	that	cells	were	treated	with	VPS34-IN1	(1	µM)	or	
GDC-0941	(0.5	µM)	for	1	hour	prior	to	stimulation	with	50	ng/ml	IGF1	for	the	indicated	
times.	
	
Figure	9	–	Loss	of	mTORC2	activity	ablates	IGF1	induced	SGK3	activity.	Wild	type	and	SIN1	
knock	out	HEK	293	cells	were	serum	starved	overnight	prior	to	50ng/ml	IGF1	stimulation	for	
15	minutes.	Endogenous	SGK3	was	immunoprecipitated	from	the	lysates	and	SGK3	kinase	
activity	assessed	by	measuring	phosphorylation	of	the	Crosstide	substrate	peptide	in	the	
presence	of	0.1	mM	32PgATP	in	a	30	min	reaction.	Both	immunoprecipitates	and	lysates	
were	subjected	to	western	blotting	with	the	indicated	antibodies.	
	
Figure	10	-	Summary	of	how	SGK3	is	activated	by	growth	factors.	Our	work	suggest	that	
three	upstream	pathways	contribute	to	SGK3	activity.	Firstly,	IGF1	stimulates	production	of	
endosomal	PtdIns(3)P	likely	through	the	UV-RAG	VPS34	complex,	thereby	recruiting	SGK3	to	
endosomes	where	it	is	activated.	Secondly,	Class	1	PI3K	stimulates	SGK3	through	enhanced	
production	of	PtdIns(3)P	resulting	from	sequential	dephosphorylation	of	PtdIns(3,4,5)P3	by	
SHIP2	and	then	INPP4A/B	inositol	phosphatases.	It	is	not	clear	where	PtdIns(3)P	generated	
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through	this	route	resides.	Thirdly,	our	data	are	consistent	with	a	model	in	which	
PtdIns(3,4,5)P3	produced	from	activation	of	Class	1	PI3K,	promotes	phosphorylation	of	the	
hydrophobic	motif	of	SGK3	by	mTORC2,	thereby	stimulating	activation	of	SGK3	by	PDK1.		
	
Figure	S1	–	Generation	of	SGK3	knock	out	and	GFP-SGK3	knock	in	cell	lines	and	the	impact	
of	hVPS34	inhibition	on	GFP-SGK3	localisation.	(A)	Wild	type	(WT),	SGK3	knock-out	(KO)	
and	GFP-GFP-SGK3	knock-in	(KI)	HEK293	cells	were	lysed	and	cell	lysates	subjected	to	
immunoblot	analysis	with	the	indicated	antibodies.	(B)	GFP-SGK3	knock-in	HEK293	cells	
cultured	in	10%	(v/v)	serum	were	treated	with	or	without	1μM	VPS34-IN1	or	1μM	SAR405	
for	1	hour	prior	to	fixation	with	4%	(v/v)	paraformaldehyde.	GFP	distribution	in	cells	was	
visualized	using	chicken	anti-GFP	primary	and	anti-chicken	Alexa	Fluor-488	to	enhance	the	
GFP	signal	(upper	panel).	DAPI	was	used	to	stain	nuclei	(lower	panel).	Histogram	represents	
quantitation	of	GFP-SGK3	on	endosomal	structures	using	sum	of	intensity	of	fluorescent	
signal	from	staining	of	GFP	±S.E.M.	following	the	various	treatments.	
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